Pseudomonas aeruginosa (PA6206), Lung Infection Model, CFU Data

  1. image
  2. image
  3. image
  4. image
CONTACT CUSTOMER SERVICE
  ADD TO FAVORITES
  ADD TO PANEL
OVERVIEW
DOCUMENTS/REFERENCES
RELATED SERVICES
RELATED PRODUCTS
BIOLOGICAL INFORMATION
BACKGROUND INFORMATION
This model assesses the efficacy of test articles for protection against a lethal lung infection with cytotoxic clinical isolate of Pseudomonas aeruginosa. It may be used to assess efficacy of small molecules, vaccines and biologics.
SPECIES
Pseudomonas aeruginosa
STRAIN COMMON NAME
#6206
ORGANISM
Gram-negative Bacteria
INCUBATION CONDITIONS
Aerobic
ASSAY INFORMATION
ASSAY TYPE
In Vivo
TESTING INFORMATION
PROCEDURE SUMMARY
Groups of 5 female specific-pathogen-free ICR mice weighing 22 ± 2 g are used. Animals are immunosuppressed by two intraperitoneal injections of cyclophosphamide, the first at 150 mg/kg 4 days before infection (day –4) and the second at 100 mg/kg, 1 day before infection (day –1). On day 0, animals are inoculated intranasally (0.02 mL/lung) of Pseudomonas aeruginosa aeruginosa (PA6206) after anesthesia with etomidate (~20 mg/kg, IV) or pentobarbital (40 mg/kg, IV). Vehicle and/or test substances are then administered (IV, PO, IP, or SC) 2 and 14 hours later. At 26 hours after inoculation, animals are euthanized with CO₂ asphyxiation and the lung tissue is harvested from each of the test animals. The tissues are homogenized in 1 ml of PBS, pH 7.4 with a homogenizer. Homogenates, 0.1 ml, are used for serial 10-fold dilutions and plated onto MacConkey II agar for colony counts.
CRITERIA FOR SIGNIFICANCE
An agent is found to be bactericidal at a given concentration if treatment results in a 2-log reduction in counts over 26 hr relative to the baseline inoculum.
TURNAROUND TIME
STANDARD
20 Days
CLINICAL RELEVANCE
THERAPEUTIC AREA
Infectious Disease
ADDITIONAL INFORMATION
BRAND
PDS
TESTING LOCATION
Taiwan - Taipei
OTHER INFORMATION
We will readily accommodate client-specified alterations. These studies are performed at our AAALAC accredited BSL-2 laboratory in Taipei, Taiwan. All aspects of this work are performed in general accordance with the Guide for the Care and Use of laboratory animals (National Academy Press, Washington, DC, 2011). The study protocol was approved by the Pharmacology Discovery Services IACUC and is performed with the oversight of veterinarians to assure the humane treatment of laboratory animals.

 

© Copyright 2026, Pharmacology Discovery Services – Privacy Policy | Cookie Notice | Cookie Preferences